Breaking: PINS Medical, SNEURO, and Haifu Medical's BCI Products Enter China's Fast-Track Green Channel

BEIJING — Three Chinese medical device companies are poised to reshape the global brain-computer interface landscape, as their flagship products enter China's fast-track regulatory approval process — a move that signals Beijing's push to dominate the next frontier of neural technology.

The Center for Medical Device Evaluation under China's National Medical Products Administration recently announced that invasive, semi-invasive, and non-invasive BCI systems from PINS Medical, SNEURO MEDICAL, and Haifu Medical respectively have been selected for the Innovative Medical Device Special Review Procedure — commonly known as the green channel.

The simultaneous approval marks a watershed moment for China's BCI industry, which until now has been characterized by fragmented development across isolated technology tracks. Now, for the first time, domestic companies have achieved breakthroughs across all three major BCI modalities — invasive, semi-invasive, and non-invasive — creating a complete technological ecosystem that rivals and potentially surpasses Western competitors.

Three Tracks, One Vision

The global BCI market has long been dominated by invasive approaches, with companies like Elon Musk's Neuralink leading the charge in implantable devices. But China's three-pronged strategy suggests a different calculus: rather than betting everything on one technology, Beijing is hedging across the entire spectrum of neural interface possibilities.

PINS Medical, founded in 2008 and based in Beijing, has spent over a decade building what is now China's most comprehensive neuromodulation product portfolio. The company's "4S" matrix — deep brain stimulation, vagus nerve stimulation, sacral neuromodulation, and spinal cord stimulation — has broken the longstanding monopoly of imported brands in China's high-end neurology market.

Their green-channel product, an implantable BCI neural stimulator, represents an evolution from traditional unidirectional electrical stimulation to closed-loop intelligent regulation. The device can sense brain signals, analyze them in real-time, and deliver precision therapy — a capability that positions PINS at the cutting edge of invasive BCI technology.

Hangzhou-based SNEURO MEDICAL takes a different approach with semi-invasive technology. The company, which has already commercialized China's first domestically developed rechargeable spinal cord stimulator, is now pushing into central-peripheral integrated neuromodulation. Their implantable tibial nerve stimulation system targets conditions ranging from chronic pain to spinal cord injury, filling a critical gap in China's high-end neurology equipment supply chain.

Perhaps most innovative is Chongqing Haifu Medical's non-invasive approach. While most BCI companies focus on electrode-based systems, Haifu has leveraged decades of expertise in focused ultrasound to create a transcranial focused ultrasound BCI regulation system. The technology claims to solve three longstanding challenges: non-invasive skull penetration, deep brain region targeting, and bidirectional neural signal interaction.

Policy Tailwinds

The green channel designation is more than a regulatory formality. Products selected for the program receive early technical guidance from review experts, helping companies avoid development pitfalls and clinical trial design flaws. The result: faster time-to-market and reduced R&D risk for breakthrough technologies.

Beijing has designated brain-computer interfaces as a strategic future industry, part of a broader push to secure technological sovereignty in areas critical to national health and advanced manufacturing. Regional governments in Zhejiang, Chongqing, and Shanghai have rolled out additional support policies, creating what officials describe as a "three-dimensional policy support system" combining national direction with local implementation.

The policy framework addresses what has long been a pain point in China's medical device sector: the gap between research breakthroughs and commercial products. By streamlining the path from laboratory to clinic, Beijing hopes to accelerate the translation of basic science into usable therapies.

The Global Race Heats Up

For years, Western companies have dominated the high-end BCI market, with products that command premium prices and remain largely inaccessible to China's vast network of grassroots medical institutions. The result has been a two-tier system: world-class technology available only in top-tier hospitals, while patients in smaller cities and rural areas go without.

China's domestic BCI ecosystem promises to change that equation. Leveraging local R&D and manufacturing capabilities, Chinese companies can produce devices at a fraction of the cost of imported alternatives — potentially democratizing access to advanced neural therapies across the country's 1.4 billion people.

The supply chain effects extend beyond the devices themselves. The three companies' technological advances are driving domestic production of upstream components — biocompatible materials, specialized chips, precision electrodes, intelligent algorithms, and acoustic devices — reducing dependence on foreign suppliers and creating a self-sustaining industrial ecosystem.

Golden Years Ahead

Industry observers expect 2026 to 2030 to be the golden period for China's BCI sector, with a wave of products moving through expedited review and reaching the market. The concentration of breakthroughs across multiple technology tracks suggests China may not just catch up to Western competitors — it could leapfrog them by offering a more diverse, more accessible, and potentially more affordable BCI ecosystem.

The implications extend beyond healthcare. Brain-computer interfaces sit at the intersection of artificial intelligence, biotechnology, and advanced manufacturing — three sectors Beijing has identified as critical to its long-term economic strategy. Success in BCI could catalyze advances across all three, creating spillover effects that reshape China's position in the global technology hierarchy.

For patients suffering from neurological conditions — from Parkinson's disease to chronic pain to spinal cord injuries — the promise is more immediate: access to cutting-edge therapies that were once the exclusive domain of the wealthy or the well-connected.

Whether China's BCI ambitions will translate into global commercial success remains to be seen. Regulatory approval is one thing; market acceptance in Western countries, with their own geopolitical considerations and domestic champions, is another. But one thing is certain: the era of Western monopoly in brain-computer interfaces is ending, and China is positioning itself to lead the next chapter.

The second Brain-Computer Interface Ecosystem Conference (iCCD2026) will be held October 28-29, 2026, in Shenzhen, bringing together industry players across the BCI value chain.